Back to News
Market Impact: 0.2
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
Source: globenewswire.com
Healthcare & Biotech
The first participant has been dosed in QUELL-DME, a Phase 2 trial evaluating BGE-102, an oral NLRP3 inhibitor, for diabetic macular edema. Topline results are anticipated in the second half of 2027; no efficacy or safety results were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Dentsply earnings missed by $0.02, revenue fell short of estimates
- US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom
- Cigna raises annual profit forecast on strength in health services unit
- Truist raises Zimmer Biomet stock price target on robotics progress
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- How to Evaluate AI Report Writers for Financial Analysis
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit